Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

rucaparib 200 MG Oral Tablet [Rubraca]

Known as: Rubraca (as rucaparib camisylate) 200 MG Oral Tablet, Rubraca 200 MG Oral Tablet, rucaparib camsylate 200 mg ORAL TABLET, FILM COATED [Rubraca] 
 
National Institutes of Health

Related topics

Related topics

13 relations
Brilliant blue FCFIndigo CarmineMagnesium stearateOral Tablet
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Rucaparip (Rubraca®) induces necrosis via upregulating the expression of RIP1 and RIP3 in ovarian cancer cells.
In the current study we investigated the inhibitory effect of rucaparib (Rubraca®) on human ovarian cancer SKOV3 and A2780 cells… Expand
Review
2019
Review
2019
Rucaparib: A Review in Ovarian Cancer
Rucaparib (Rubraca®) is a small molecule poly(ADP-ribose) polymerase (PARP) inhibitor with potent activity against PARP-1, -2 and… Expand
  • table 1
  • figure 1
Review
2017
Review
2017
Rucaparib: First Global Approval
Rucaparib (Rubraca™) is an oral, small molecule, poly (ADP-ribose) polymerase inhibitor being developed by Clovis Oncology, Inc… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE